#2025-106Law No. 2025-106 on Improving Breast Cancer Treatment Coverage
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
Law No. 2025-106 establishes comprehensive coverage for breast cancer treatment in France, ensuring that all specific care and devices related to breast cancer treatment and its aftermath are entirely reimbursed by health insurance organizations. The law mandates that oncologists provide detailed information on available support care and creates a specific fund for non-reimbursable services related to breast cancer treatment. Additionally, it allows for capping out-of-pocket expenses for reconstructive surgeries post-cancer treatment.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Creation of full reimbursement for breast cancer treatment-related care and devices.
- Requirement for oncologists to provide patients with information on available support care.
- Establishment of a fund for non-reimbursable services related to breast cancer treatment.
Obligations
What this law requires
Health insurance organizations must provide full reimbursement for prescribed breast cancer treatment-related care and devices that have specific characteristics to breast cancer treatment or its aftermath, within the limits of tariffs established under Article L. 160-8 of the Social Security Code.
Oncologists must provide detailed information to patients about available support care in their region and invite them to consult the regional support care directory before treatment begins.
The Government must issue ministerial decrees defining the specific care and devices covered under Article L. 16-11-1, including dermopigmentation, specialized undergarments, and prosthesis renewal, after consulting patient representative associations and health professional unions.
The Government must establish a specific fund amount and define eligible non-reimbursable breast cancer-related care and devices by ministerial decree, after consulting the High Health Authority and relevant national health and safety agencies.
The Government must submit a report to Parliament within six months addressing the regulation of permanent three-dimensional areolar tattooing for mastectomy patients and the conditions of its reimbursement.